BioCatalyst

Livmoniplimab, Budigalimab, Durvalumab, Atezolizumab — catalyst calendar

1 verified catalyst event(s) referencing Livmoniplimab, Budigalimab, Durvalumab, Atezolizumab, each linked to its official source. Verified as of 2026-09-23.

Upcoming

DateEventCompanyDrugOfficial source & verification
2027-01 (month)
in 3mo
ESTIMATED
 READOUT
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Li
Phase 2/3 · Hepatocellular Carcinoma
 ABBV AbbVie Inc. Livmoniplimab, Budigalimab, Durvalumab, ClinicalTrials.gov ↗
✓ Source-checked 2026-09-23
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.